// App-Quantinova.ai

: Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT).

Researchers

Presenter

  • Satoshi Nara

Principal Investigators

  • Gakuto Ogawa

  • Tomoko Kataoka

  • Yusuke Sano

  • Minoru Esaki

  • Hiroaki Nagano

  • Masatoshi Kudo

  • Masafumi Ikeda

  • Masashi Kanai

  • Ichiro Yasuda

  • Kentaro Yamazaki

  • Hirofumi Shirakawa

  • Shogo Kobayashi

  • Masato Ozaka

  • Naoto Gotohda

  • Etsuro Hatano

  • Junji Furuse

  • Takuji Okusaka

  • Makoto Ueno

Medical Centers

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Japan, Shizuoka, Japan

  • Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan

  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University, Ube, Japan

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • Department of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan

  • JCOG Data Center/ Operation Office, National Cancer Center Hospital, Tokyo, Japan

  • Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Utsunomiya, Japan

  • Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

  • Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan

  • Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • Oncology Center, Yamaguchi University Hospital, Ube, Japan

  • Third Department of Internal Medicine, University of Toyama, Toyama, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Adenosquamous carcinoma

  • Advanced biliary tract carcinoma

  • Gallbladder cancer

  • Ampullary carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • III

Study Id's

  • JCOG1920

  • JCOG1202

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved